Kevin Rakin is co-founder of HighCape Partners and brings more than 25 years of experience as an executive and investor in the life sciences industry. He most recently served as President of Shire Regenerative Medicine. Prior to joining Shire, Mr. Rakin was Chairman and Chief Executive Officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011 for $750M. Before that, he served as an executive-in- residence at Canaan Partners. Previously, he was a Co-Founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly traded pharmacogenomics company, until its merger with Clinical Data, Inc. in 2005. His Board memberships include Aziyo Biologics, Inc. (Chairman), Cheetah Medical, Inc. (Chairman), Cybrexa, Inc., and TELA Bio, Inc., as well as Histogenics Corp. and Collagen Matrix, Inc.
He has previously served as a Board member for Ipsogen SA, Vion Pharmaceuticals, Inc., OMRIX Biopharmaceuticals, Inc., and Clinical Data, Inc. Mr. Rakin received an M.B.A. from Columbia University and B.Com and B.Com (Hons) degrees from the University of Cape Town, South Africa.
Matt Zuga is co-founder of HighCape Partners, and brings more than 20 years of life sciences investment and banking experience. Mr. Zuga was formerly a Managing Director of Syngenta Ventures, an investment vehicle of Syngenta Corp. He was a founder and managing member of Red Abbey Venture Partners (RAVP), where he is currently a member of the Investment Committee.
His current board memberships include Aziyo Biologics and Alba Therapeutics (Co-Chairman). He has previously served as a Board member for Arginetix, Inc. and Board observer at Advanced BioHealing, Aegerion Pharmaceutical, Sirtris Pharmaceuticals and Stromedix, Inc. Prior to RAVP, Mr. Zuga was Head of Life Sciences investment banking at Legg Mason. Mr. Zuga received an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from The Ohio State University.
Jennifer Barretta brings 20 years of human resources experience to HighCape Partners. She currently provides consulting expertise to HighCape portfolio companies in all aspects of human resource management and leadership development. Ms. Barretta most recently held the position of Vice President of Human Resources for Shire Regenerative Medicine from 2011 to 2012. Prior to that, Ms. Barretta served as Vice President of Human Resources for Advanced BioHealing from 2006 until its acquisition by Shire in 2011, where she led the human resources function through a period of tremendous maturity as the company grew from 8 to over 500 employees during her tenure. Prior to Advanced BioHealing, Ms. Barretta was at Genaissance Pharmaceuticals, Inc. until its merger with Clinical Data, Inc. in 2005. She holds a B.S. in Business Management from Syracuse University.
Dean Tozer has more than 25 years of experience in the global healthcare industry with an established track record of successfully launching and marketing innovative technologies. He most recently served as President & Chief Executive Officer of Nuo Therapeutics. Prior to joining Nuo he was Vice President of Corporate Development for Shire Regenerative Medicine, which acquired Advanced BIoHealing in 2011, where he was Senior Vice President. He is widely regarded as a key architect of the commercial strategy behind the re-launch and subsequent success of Dermagraft in the U.S. market. Prior to these roles, he spent 10 years in the global pharmaceutical industry
He currently serves as a Board member of Zipline Medical and BLDG Active. From 2009 to 2013, Mr. Tozer also served as a founding executive and officer of The Alliance for Regenerative Medicine. He received a Bachelor of Commerce degree from Saint Mary’s University in Halifax, Nova Scotia and a Certified Management Accountant designation in Ontario, Canada.
Dr. Charles Hart brings over 35 years of research and development experience in the biotechnology field. Dr. Hart most recently held the position of Vice President of Research for Shire Regenerative Medicine from 2011 to 2013. Prior to joining Shire, Dr. Hart served as Vice President and Chief Scientific Officer at Advanced BioHealing from 2008 until its acquisition by Shire in 2011. From 2004 to 2008, he served as Vice President and Chief Scientific Officer at BioMimetic Therapeutics, a company focused on the development of products for the treatment of musculoskeletal injuries. Previous to that, he spent 21 years at ZymoGenetics, Inc., a biotchnology company focused on protein therapeutics, where he held a variety of leadership positions. He currently serves as a Board member of the Davis House Child Advocacy Center. Dr. Hart has authored over 60 scientific publications and holds over 45 U.S. patents. He received his Ph.D. from the University of Washington, his M.S. from Oregon State University and his B.S. from the University of California at Davis.
Dr. Carol Reed has over 15 years of experience in drug and device development in the areas of pulmonary diseases, psychiatry, cardiology, gastroenterology and infectious diseases, in addition to 10 years’ experience as a physician in the practice of pulmonary and critical care medicine. Now an independent consultant, Dr. Reed was Chief Medical Officer and Executive Vice President at Clinical Data, Inc. from 2005 through 2011 where she was responsible for the development and approval by the U.S. Food and Drug Administration of the antidepressant VIIBRYD®, and for the launch of DNA sequencing tests for cardiac genetic disorders including Long QT Syndrome. Prior to this time, Dr. Reed was Vice President, Medical Affairs at Genaissance Pharmaceuticals. Dr. Reed earned an MD from the Rush Medical College in Chicago and an M.S. in Biology from the University of Illinois at Chicago. She is a Fellow of the American College of Physicians and the American College of Chest Physicians.
Dr. Seth Rudnick brings to HighCape over 17 years of investment experience and an additional 20 years of experience as an executive in the life sciences industry. Dr. Rudnick most recently served as a Partner at Canaan Partners, a global venture capital firm. He is well known for his expertise in healthcare investing and has worked closely with numerous companies to develop novel therapeutic products. In 2006 and 2007, Dr. Rudnick was named to the Forbes Midas List, a ranking of the top venture capitalists in technology and life sciences. Prior to Canaan, Dr. Rudnick served as CEO and Chairman of Cyto Therapeutics, a developer of stem cell-based therapies to combat chronic diseases. Additionally, he helped start and headed research and development for Ortho Biotech, a division of Johnson & Johnson where he was instrumental in creating a portfolio of products that still generate significant Johnson & Johnson revenue today. He began his career at Schering-Plough and also directed pharmaceutical development efforts at Biogen. Dr. Rudnick was a Yale Fellow in medical oncology where he was a Robert Wood Johnson Scholar. He earned his medical degree at the University of Virginia and holds a B.A. in history from the University of Pennsylvania. Dr. Rudnick currently sits on the boards of Abyrx, Liquidia Technologies, Pozen, SpineWave, VaxInnate, and Square 1 Bank.
David Colpman is a Senior Advisor to HighCape and brings over 20 years of experience in business development, licensing, and strategy. Mr. Colpman established Colpman Consulting which delivers strategic BD advice to biotech and pharma sectors, with emphasis on Europe. Colpman Consulting identified Johnson and Johnson as the out-licensing partner to Alligator AB’s immuno-oncology agent for $700M. Colpman Consulting was also the sole business advisor on the sale of Cormorant AB and its early stage IL8 antibody to BMS for up to $520M, including an upfront and milestone payments. Mr. Colpman served as Purdue Pharma’s Interim Head of BD, and currently serves on the Board for Orexo AB and HRA Pharma. He formerly served on the Board of ACE Biosciences and is a longstanding advisor to Sunstone Capital.
Mr. Colpman joined Shire in 1999 and was instrumental in delivering the M&A and licensing strategy, which has today created a company valued at $55B. As a direct report to the CEO, Mr. Colpman completed approximately 30 deals, including the $4.2bn acquisition of ViroPharma and the $160M acquisition of Sarcode. Earlier in his career at Shire he identified and led the acquisition of TKT, which went on to become the cornerstone of Shire’s successful rare disease business. He also in-licensed Lialda, which has become the sector leader in ulcerative colitis with sales of $700M.
Previously, Mr. Colpman headed Licensing and Alliances at Novo Nordisk in Denmark and spent two years in BD at Glaxo Wellcome UK. He is a pharmacist by training.